Why the study?
Does DITPA improve a composite endpoint of symptoms and morbidity/mortality in patients with NYHA class II to IV congestive heart failure?
Population
86 patients with New York Heart Association (NYHA) class II to IV congestive heart failure
Comparison
DITPA treated for 6 months vs Placebo
Design
RCT, 2:1 to DITPA or placebo, double-blind
Follow-up
6 months
Authors
Loading...
DITPA should not be used in heart failure; challenges reliance on hemodynamic surrogates for symptomatic benefit in thyroid analog development.
Does DITPA improve a composite endpoint of symptoms and morbidity/mortality in patients with NYHA class II to IV congestive heart failure?
Although the thyroid hormone analog DITPA improves hemodynamic and metabolic parameters in patients with heart failure, it is poorly tolerated and does not provide symptomatic benefit.
Goldman et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: